Drug
Efzofitimod
Status:
Phase 3
Condition:
Sarcoidosis ILD
Intervention Type:
Intravenous (IV) Injection
Funder Type:
Industry
Drug Details
Efzofitimod is a tRNA synthetase-derived therapy based on a naturally occurring, lung-enriched, splice variant of histidyl-tRNA synthetase (HARS). Efzofitimod selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve inflammation without immune suppression and potentially prevent the progression of fibrosis. NRP2 is a new immune target in ILD that is upstream of other therapeutic targets, which allows it to hit multiple inflammatory and pro-fibrotic pathways, addressing the complex immune pathology observed in ILD.
Study Purpose
This is a multicenter, randomized, double-blind, placebo-controlled, study comparing the efficacy and safety of intravenous (IV) efzofitimod 3 mg/kg and 5 mg/kg versus placebo after 48 weeks of treatment. This study will enroll adults with histologically confirmed pulmonary sarcoidosis receiving stable treatment with oral corticosteroid (OCS), with or without immunosuppressant therapy.
This drug has no clinical trials actively recruiting patients at this time.